Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 2003 Aug;37(2):150-4 PMID: 12883301

Pubmed ID

12883301

Abstract

Dermatologic extraintestinal manifestations of Crohn disease may be refractory to treatment with corticosteroids and immunomodulators. The authors describe four children with Crohn disease with dermatologic manifestations: pyoderma gangrenosum, orofacial involvement, erythema nodosum, and idiopathic lymphedema. These dermatologic conditions were unresponsive to conventional therapy but had rapid and sustained response to the anti-TNF-alpha antibody infliximab. No adverse reactions occurred. Infliximab should be considered for treating the extraintestinal dermatologic manifestations of Crohn disease in children.

Author List

Kugathasan S, Miranda A, Nocton J, Drolet BA, Raasch C, Binion DG

Authors

Beth A. Drolet MD Professor in the Dermatology department at Medical College of Wisconsin
Adrian Miranda MD Clinical Professor in the Pediatrics department at Medical College of Wisconsin




Scopus

2-s2.0-1542707085   75 Citations

MESH terms used to index this publication - Major topics in bold

Adolescent
Antibodies, Monoclonal
Child
Crohn Disease
Dermatologic Agents
Erythema Nodosum
Humans
Infliximab
Lymphedema
Male
Pyoderma Gangrenosum
Treatment Outcome
jenkins-FCD Prod-299 9ef562391eceb2b8f95265c767fbba1ce5a52fd6